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The Covid-19 pandemic has turned the healthcare world upside down. Research and medical
institutions have delved deeply into healthcare arsenals to identify some unlikely heroes that
have helped to treat a disease that seemingly evolves with each passing day. In a controlled, open
label trial of hospitalized Covid-19 patients, the RECOVERY Collaborative Group found that
the use of dexamethasone, a cheap, generic drug commonly used to treat a variety of
inflammatory conditions, resulted in lower 28 day mortality in Covid-19 patients receiving
respiratory support.1 This is not the only incidence of older, generic drugs being repurposed to
combat the SARS-CoV-2 virus; however, it is one of the more successful stories. The urgency to
find effectiveness in older drugs has come with some serious pitfalls. Chloroquine phosphate and
hydroxychloroquine sulfate, two drugs originally used for malaria, were broadcasted at the
beginning of the pandemic as possible “cures” against the new virus. Ensuing demand for these
products threatened to interrupt chronic therapy among patients using the drugs for evidencebased indications such as lupus, only for the Food and Drug Administration (FDA) to revoke
their Emergency Use Authorization (EUA) for COVID-19 due to reports of ineffectiveness and
serious cardiac adverse events.2
Drug repurposing is a process which involves identifying an alternative use for medications that
are already on the market or investigational medications that are being studied for a different
indication. For patients with limited life expectancy or few treatment options, earlier access to
potential new therapeutics is a benefit of repurposing older cheaper drugs that are already on the
market. For example, GLP-1 agonists, indicated for type 2 diabetes, are being integrated in
clinical practice for patients with nonalcoholic steatohepatitis based on evidence from a mix of
clinical trials and observational studies.5 A major advantage of drug repurposing is that
preclinical and safety studies have already been conducted, and for medications that have been
approved, there exists a body of real-world evidence on utilization and safety.3 Therefore, the
safety profile of the medications is already well understood and fewer studies will need to be
conducted for regulatory approval, which may shorten the notoriously long drug development
process significantly. This decreases the cost of development and reduces the risk of failure in
the later stages of clinical development to much lower levels compared with a completely new
molecular entity.3 Although less costly, 3 years of market protection provided by the FDA is
often not enough time to recover accumulated expenses, and may leave the company open to
competition from off-label use of generics.4 Consequently, there have been relatively few
instances of pharmaceutical companies seeking and gaining approval for new indications of
repurposed generic drugs.
There are different methods for identifying candidate drugs for repurposing including
computational approaches and experimental approaches. Computational approaches include
analysis of genomic and proteomic data, chemical structure and retrospective observational
studies .4 Observational studies occupy a critical intermediary position in the drug repurposing
process. They are one of the more accessible pathways for developing evidence to support the
drug repurposing efforts, capitalizing on already existing data that only needs to be extracted and

not created. Once drugs are identified as potential candidates for repurposing (e.g., based on an
understanding of their mechanisms of action), observational studies that leverage existing data
sources can identify signals of clinical effectiveness (or a lack thereof) to support or refute the
need for expensive clinical trials, while also informing trial design. Positive signals from
observational studies should be confirmed with randomized controlled trials before repurposed
drugs are integrated into clinical practice.
Electronic health records (EHRs), administrative databases (e.g., healthcare claims), and
registries are a common resource utilized for observational studies of drugs being examined for
repurposing.4 EHRs have assets of large amount of data on structured patient outcomes including
laboratory tests, drug prescribing data, and diagnostic and pathophysiologic data. EHRs also
contain an abundance of unstructured data including signs and symptoms of a specific disease
and imaging data. These rich data sources, sometimes referred to as “big data,” can support
rigorous drug development research. Due to substantial diversity in EHR systems used to host
this type of data, there is a need for technological and automation solutions for appropriate
analysis. However large data sources, like EHRs, are beneficial for multiple reasons. First, in
large datasets, it is easier to find multiple signals of effectiveness (e.g., changes in
symptomatology and healthcare utilization). Second, large sample sizes allow for increased
power at lower cost, facilitating detection of smaller effect sizes than would be identified in a
small clinical trial. This is important because a modest statistical effect size can have large
clinical implications. Third, since the data have already been collected, studies that use large
existing databases to test hypotheses regarding new indications can be conducted within months
rather than years.
Researchers seeking to conduct observational research to support drug repurposing may
encounter several challenges. Access to big data in a format that is suitable for rigorous
pharmacoepidemiologic research is typically tightly restricted to protect patient privacy.
Distributed research networks such as the FDA’s Sentinel Initiative and the Health Care Systems
Research Network overcome such barriers by applying common data models and permitting
individual institutions to maintain local control over their data resources, while allowing external
scientists to implement protocols that use their data as part of larger studies involving data from
several organizations.6,7 Although analysis of data across institutions would traditionally have
required substantial staff time to adapt code to address the nuances of each organization’s data
model, use of a common data model is comparatively much more efficient. An individual analyst
can develop a standard program that can be run in parallel on-site at each organization, with the
aggregate results later combined without any need to exchange sensitive personal health
information. This is not to say that progress in expanding access to “big data” is not needed.
Access to these types of research networks is often closed to researchers unaffiliated with
participating institutions, or may be costly, as is the case with data from the Centers for Medicare
and Medicaid Services.8 Efforts should be made to allocate resources and establish processes to

ensure that data are not only organized in a standardized format but also widely usable by
researchers.
It is evident that drug repurposing cannot be done without a wealth of resources often housed at
different institutions. The likely partners for drug repurposing initiatives include large
pharmaceutical companies who have libraries of compounds, academic institutions with diverse
areas of scientific expertise, and government agencies who are data stewards and are able to fund
grants that promote public health.9 Pharmaceutical companies can act as the backbone for
projects because they contain the molecular libraries and preliminary safety data that can serve as
the foundation for successful ventures. Moreover, these companies have cross-functional teams
that are already well-versed in regulatory drug approval processes and can streamline
successfully repurposed drugs through FDA reviews. Small, upstart biotech companies should
also be included to take advantage of their new and innovative methods in drug development.9
Funding of such projects is a large burden that can be relieved by government led programs such
as the Discovering New Therapeutic Uses for Existing Molecules initiative by the NIH-National
Center for Advancing Translational Sciences (NIH-NCATS) of which has already partnered with
eight pharmaceutical companies.4 For Covid-19 specifically, the US Defense Advanced Research
Projects Agency (DARPA) has signed a $16 million contract with the Wyss Institute for
Biologically Inspired Engineering at Harvard University to identify and test FDA approved drugs
to treat or prevent Covid-19.10 Researchers should also turn to non-profit organizations such as
Cures Within Reach, the Michael J. Fox Foundation, and the Alzheimer’s Drug Discovery
Foundation who also have funded programs for drug repurposing studies and can bring in a
much needed patient perspective on access and unmet needs.9 Only through strategic, crosssectoral partnerships can current and future drug repurposing studies be translated into new
therapeutic options that ultimately benefit patients.
The COVID-19 pandemic has shown us that both the medical community and general public are
interested in drug repurposing. Although drug repurposing represents an opportunity for faster
access to new therapeutic options compared with development of new molecular entities, it is
important to note that lowering established evidentiary thresholds and pushing new therapeutic
applications into the clinic on the back of preliminary results is not what drug repurposing aims
to do. The repurposing of hydroxychloroquine, for which the EUA was rushed without sufficient
evidence, represents a cautionary example. It is paramount that scientists within industry,
academic, and regulatory settings apply the consistently high standards for evidence of safety
and effectiveness that have been established for new molecular entities to repurposed drugs as
well. In our modern era where scientific expertise is actively undermined in the public sphere,
the scientific community’s transparent stewardship of public health has only become more
important. Ultimately, a systematic, collaborative, and well-resourced initiative to discover and
study new indications for existing drugs may help fulfill the nation’s thirst for more therapeutic
options and lower pharmaceutical costs.
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